{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:50:06Z","timestamp":1791474606165,"version":"4.3.4"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T00:00:00Z","timestamp":1715472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002800","name":"Desmoid Tumor Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002800","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ejca.2024.114119","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T01:51:15Z","timestamp":1715651475000},"page":"114119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study"],"prefix":"10.1016","volume":"205","author":[{"given":"Jonathan","family":"Noujaim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abha A.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline L.","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirrtha","family":"Srikanthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lemieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagit Peretz","family":"Soroka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Tibout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Turcotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albiruni R.","family":"Abdul Razak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippos","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejca.2024.114119_bib1","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1634\/theoncologist.2010-0281","article-title":"Desmoid tumors: clinical features and treatment options for advanced disease","volume":"16","author":"Kasper","year":"2011","journal-title":"oncologist"},{"key":"10.1016\/j.ejca.2024.114119_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2022.102114","article-title":"The epidemiology of desmoid tumors in Denmark","volume":"77","author":"Anneberg","year":"2022","journal-title":"Cancer Epidemiol"},{"issue":"4","key":"10.1016\/j.ejca.2024.114119_bib3","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/CCO.0b013e32832c9502","article-title":"Desmoid tumor: from surgical extirpation to molecular dissection","volume":"21","author":"Lazar","year":"2009","journal-title":"Curr Opin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2024.114119_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100578","article-title":"Association between recent pregnancy or hormonal contraceptive exposure and outcome of desmoid-type fibromatosis","volume":"7","author":"Debaudringhien","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2024.114119_bib5","doi-asserted-by":"crossref","unstructured":"Colombo C., Fiore M., Grignani G., Tolomeo F., Merlini A., Palassini E., et al. A prospective observational study of Active surveillance in primary desmoid fibromatosis. Clin Cancer Res, 2022.","DOI":"10.1158\/1078-0432.c.6532638"},{"issue":"7","key":"10.1016\/j.ejca.2024.114119_bib6","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1200\/JCO.2003.05.150","article-title":"Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution","volume":"21","author":"Gronchi","year":"2003","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2024.114119_bib7","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2106\/JBJS.M.00988","article-title":"Larousserie Fdr, Anract P, et al. Wait-and-see policy as a first-line management for extra-abdominal desmoid tumors","volume":"96","author":"Briand","year":"2014","journal-title":"JBJS J Bone Jt Surg"},{"issue":"5","key":"10.1016\/j.ejca.2024.114119_bib8","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/1097-0142(20010901)92:5<1259::AID-CNCR1446>3.0.CO;2-Y","article-title":"Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis","volume":"92","author":"Azzarelli","year":"2001","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2024.114119_bib9","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S1470-2045(19)30276-1","article-title":"Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study","volume":"20","author":"Toulmonde","year":"2019","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2024.114119_bib10","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1016\/j.ejca.2009.08.016","article-title":"Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis","volume":"45","author":"Constantinidou","year":"2009","journal-title":"Eur J Cancer"},{"issue":"25","key":"10.1016\/j.ejca.2024.114119_bib11","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1805052","article-title":"Sorafenib for advanced and refractory desmoid tumors","volume":"379","author":"Gounder","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114119_bib12","doi-asserted-by":"crossref","unstructured":"Gounder Mrinal M.M. Sorafenib for Advanced and Refractory Desmoid Tumors. New England Journal of Medicine.379(25):2417\u20132428.","DOI":"10.1056\/NEJMoa1805052"},{"issue":"13","key":"10.1016\/j.ejca.2024.114119_bib13","doi-asserted-by":"crossref","first-page":"8653","DOI":"10.1245\/s10434-023-14341-2","article-title":"Initial active surveillance strategy for patients with peripheral sporadic primary desmoid-type fibromatosis: a multicentric phase II observational trial","volume":"30","author":"Bonvalot","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2024.114119_bib14","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejca.2019.11.013","article-title":"The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients","volume":"127","author":"ANON","year":"2020","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2024.114119_bib15","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa2210140","article-title":"Nirogacestat, a \u03b3-secretase inhibitor for desmoid tumors","volume":"388","author":"Gounder","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114119_bib16","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2023.03.017","article-title":"Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: a need to review dose","volume":"186","author":"Garg","year":"2023","journal-title":"Eur J Cancer"},{"issue":"suppl_2)","key":"10.1016\/j.ejca.2024.114119_bib17","article-title":"The clinico-radiological outcome of desmoid type-fibromatosis after discontinuing the sorafenib treatment in responders: Single-arm phase II clinical trial","volume":"34","author":"Bharath SR","year":"2023","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.114119_bib18","doi-asserted-by":"crossref","DOI":"10.1148\/rycan.2021210016","article-title":"MRI volumetrics and image texture analysis in assessing systemic treatment response in extra-abdominal desmoid fibromatosis","volume":"3","author":"Subhawong","year":"2021","journal-title":"Radio Imaging Cancer"},{"key":"10.1016\/j.ejca.2024.114119_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1286807","article-title":"MRI T2 mapping assessment of T2 relaxation time in desmoid tumors as a quantitative imaging biomarker of tumor response: preliminary results","volume":"13","author":"Souza","year":"2023","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2024.114119_bib20","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1158\/1078-0432.CCR-23-2313","article-title":"PDGFR\u03b2 signaling cooperates with \u03b2-catenin to modulate c-Abl and biologic behavior of desmoid-type fibromatosis","volume":"30","author":"Hu","year":"2024","journal-title":"Clin Cancer Res"}],"updated-by":[{"DOI":"10.1016\/j.ejca.2024.114221","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000}}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924007755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924007755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T01:24:15Z","timestamp":1726104255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924007755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":20,"alternative-id":["S0959804924007755"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114119","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ejca.2024.114221","asserted-by":"object"}]},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114119","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"114119"}}